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cost 0.2 % to 58.01 % of the average monthly salary of the patient. In 2014, the least 
affordable drugs for patients with COPD were drugs from the inhaled corticosteroids 
group: Flixotide nebules, Nebufluzone and Pulmicort, the cost of which varied from 
19.86% to 58.01%, which can be afforded only by patients with incomes above the 
average. The most affordable drug is a short-acting β 2-agonist– salbutamol (Ca.s. 0.43-
15.70%). ConClusions: Ukraine faces a rather difficult situation for patients with 
COPD. Drugs recommended by GOLD are presented insufficiently, and a large number 
of drugs available in the market are not readily available to patients.
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CoSt And ReSouRCe utilizAtion of unContRolled And PeRSiStent 
ASthmA in CAnAdA: A SyStemAtiC liteRAtuRe Review
Lachaine J1, Bibeau J1, Castonguay A1, Barakat S2
1University of Montreal, Montreal, QC, Canada, 2Teva Canada Innovation, Montreal, QC, Canada
objeCtives: Asthma is a chronic inflammatory airway disease that causes a 
significant economic and humanistic burden. The objective of this study was to 
systematically review the evidence on cost and resource utilization in uncontrolled 
and persistent asthmatic patients in Canada. Methods: A literature search was 
performed using keywords such as “asthma”, “hospitalization”, “medical services”, 
and “cost”. The search was conducted in the MEDLINE, EMBASE and PubMed elec-
tronic databases from January 1st 2005 to May 28th, 2015. To be eligible, studies had 
to be Canadian, focus on uncontrolled or persistent asthma and include cost or 
resource utilization data. Results: The search retrieved 17,335 studies of which 
7 fulfilled the eligibility criteria. Among the 7 retrieved studies on uncontrolled or 
persistent asthma, 6 reported resource utilization data and 3 reported cost data. 
Among the resource utilization studies, 6 reported data on hospitalizations, 4 on 
emergency department (ED) visits and 3 on physician visits at a patient-level. The 
hospitalization rate ranged from 15% to 64.5% per patient per year and the mean 
hospitalization length of stay was 1.83 days. The rates for ED visits ranged from 
3.4% to 50.4% with 2 studies reporting rates over 20%. One study reported a mean 
physician-visit rate of 50% per patient per year while another study reported that 
64.3% of the patients had at least 4 physician-visits per year. In the cost studies, 
the total mean direct cost in adjusted 2015CDN$ per patient per year ranged 
from $413 to $1,764, carrying overall additional cost for uncontrolled asthma to 
nearly $189 million annually in Canada. ConClusions: This analysis indicates 
that uncontrolled and persistent asthma is associated with considerable cost and 
resource use, especially regarding hospitalizations, ED visits and physician visits 
at a patient-level, thus leading to an important economic burden at a population-
level in Canada.
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ASSeSing the net fiSCAl ConSequenCeS of tobACCo uSe in A high 
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objeCtives: Greece has increasing prevalence of tobacco use and one of the 
highest consumption rates in Europe. Notwithstanding that tobacco tax is an 
important fiscal revenue, smoking represents a major public health threat causing 
premature mortality, morbidity, costs and foregone productivity which are a major 
source of fiscal loss. The objective of this study was to assess the net fiscal impact 
of hypothetic tax increases to inform public policy. Methods: Evidence for the 
prevalence of smoking and smoking-attributable mortality (SAM) in Greece was 
synthesized with economic data to assess the net fiscal impact of tobacco use. 
SAM was converted into productivity (earnings) loss and tax revenue (fiscal) loss. 
Mincer functions were used to project lifetime earnings and direct and indirect per 
person tax for smokers and ex-smokers. Average tobacco consumption was used to 
quantify the expected tax revenue from tobacco consumption tax and published 
price elasticities were employed to explore the impact of hypothetical tax and 
price increases. Results: The averted mortality, by a 10% increase in the price of 
tobacco products, is expected to avert productivity loss of € 4.4-6.9 million that cor-
responds to averted fiscal loss of € 1.5-2.5 million as measured by expected lifetime 
tax. Based on previous studies, healthcare cost savings were estimated by previous 
studies at € 24-€ 149 million. Higher price increases yielded higher epidemiological, 
societal and fiscal benefits. Tobacco consumption appears to be inelastic thus, tax 
revenue was not reduced in the absence of lower consumption. ConClusions: 
Smoking represents both a source of fiscal revenue and loss for central govern-
ment. Price increases, through tobacco tax, may be a fiscally meaningful pol-
icy for reducing the burden of smoking. Although there are likely to be upper 
limits to which further tax increases will not discourage tobacco consumption. 
Assessing the net fiscal impact may be a useful tool for tobacco-control policy 
evaluation.
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objeCtives: Exacerbations of COPD contribute to overall disease severity and can 
be an important driver of increased healthcare resource utilisation. This study 
aimed to estimate COPD exacerbation rates and assess primary and secondary care 
resource utilisation in England, using GOLD 2013 categories from A: low risk, less 
symptoms to D: high risk, more symptoms. Methods: Patients with a diagnosis 
of COPD aged ≥ 40 years before January 1, 2011, registered in the Clinical Practice 
Research Datalink linked to Hospital Episode Statistics with complete spirometric 
and modified Medical Research Council Dyspnoea Scale information and exacer-
bation history were included and further classified into GOLD risk groups. Patient 
characteristics were described at baseline. Study outcomes were exacerbations 
rates, and resource utilisation comprised of general practitioner (GP) visits and 
77% in 2003 to 72% in 2012, only generic increased from 7% to 9% and mixed from 
16% to 19%. In 2012 the proportion generic dispenses was highest for salbutamol with 
53% in children and 51% in adults. ConClusions: Generic dispensing is increasing, 
probably due to preferential policy of the Dutch healthcare insurances. Switching 
drugs may increase confusion and mistakes in inhalation technique, causing less 
effective treatment and lower adherence.
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do CliniCAl guideline imPlementAtionS ReduCe the goveRnment 
budget? A CliniCAl guideline-bASed budget imPACt model in 
ReimbuRSement of inhAleR tReAtmentS in CoPd
Gungor C, Konya A, Keskinaslan A
Novartis AG, Istanbul, Turkey
objeCtives: COPD market is highly boosted by combinations caused by over-
treatment and misclassification of the patients. Physicians have high tendency 
to prescribe triple combinations for COPD patients without making classification 
for severity. The objective of this analysis is to develop a clinical guideline based 
budget impact model for COPD to inform reimbursement decision. Methods: 
A model was developed to estimate the four-year budget impact of gradually 
increasing compliance with clinical guideline based treatment in COPD patients 
who are currently under overtreatment. Only inhaler drug acquisition costs from 
payer perspective were considered for each treatment class defined in the guide-
line. Inputs for the model were derived from 2 studies to compare the inhaler 
consumption in practice and guideline recommendation by categories. Patient per-
centage and treatment class used in each category are obtained from ALPHABET 
study, projected to the currently treated COPD population in Turkey. Indacaterol, 
a LABA, was taken into account as a first step of complying with guideline-based 
treatment approach based on its superior outcomes in first line medication. The 
model did not account for patient co-payments, drug prices are assumed to be 
constant in 4 years. Results: For a COPD market with a treatment regimen 
gradually complying with GOLD guideline in 4 years, the model estimated 20%( 
mioTL -24.7) cost reduction in government budget. From first to fourth year, the 
impact is -13%(mioTL-5.8),-17%(mioTL-6.0),-22%(mioTL-6.3) and -26%(mioTL-6.6) 
respectively. ConClusions: The model budget impact of implementing clinical 
guidelines with evolving treatment regimen towards LABA and LAMA combina-
tions and its mono components may reduce the overuse of drugs and government 
spending on COPD treatments. Based on these assumptions, budget impact of 
future treatment that will help physicians to comply with treatment guidelines 
may change. Model can be adapted accordingly. Reimbursement bodies might be 
better off moving toward aligning reimbursement decisions with clinical guide-
lines in the future.
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Study of ACute loweR ReSPiRAtoRy tRACt infeCtionS in ChildRen of 
Age gRouP 1 month to 5 yeARS
Kanneganti S
Acharya Nagarjuna University, Guntur, India
objeCtives: 1) To study the clinical, radiological and epidemiological features of severe 
pneumonia in children in age group of 1 month to 5 years of age; 2) To correlate clinical 
findings with radiological and bacteriological examination; 3) To know the choice of 
antibiotic for severe pneumonia. Methods: This was a prospective clinical study of 
severe pneumonia conducted on 200 children who were admitted to pediatric wards 
from October 2010 to September 2012 at Gout General Hospital, Guntur. The epidemio-
logical factors affecting the same were also studied. Results: Age groups/Number of 
cases Percentage: 1m–6m/67 33.5; 7m–12m/52 26; 13m–60m/81 40.5. Table 1: Distribution 
of cases according to age Sex Number of cases Percentage Male 130 65 Females 70 35 
Table 2: Distribution of cases according to sex Symptoms Number Percentage Cough 
199 99. 5 Fever 184 92 Hurried breathing 200 100 Refusal of feeds 80 40 Wheeze 50 25 
Convulsions 15 7. 5 Cyanosis 8 4 Table 3: Showing various symptoms ConClusions: 
ARI, especially severe pneumonia is one of the major causes of morbidity and mortality 
in children. Bronchopneumonia is the predominant form of presentation in infants and 
preschool children. Among the risk factors studied, inappropriate immunization for 
age, anemia, PEM grade III and IV were significant risk factors in severe pneumonia. 
Symptoms and signs mentioned in the WHO ARI control programme were very sensi-
tive and can be applied to hospitalized children. Chest X-ray is a valuable aid in the 
diagnosis of pneumonia in children. Follow up chest roentgenogram is vital for evaluat-
ing the response to treatment in pneumonia. Crystalline Penicillin and amikacin are 
still the antibiotics of choice in pneumonia. Indiscriminate use of higher antibiotics in 
not justified, in view of emergence of drug resistant organisms.
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AvAilAbility of dRugS ReCommended by globAl initiAtive foR 
ChRoniC obStRuCtive lung diSeASe (gold) foR ukRAiniAn PAtientS 
with CoPd
Iakovlieva L, Bondarenko D, Matyashova N, Tkachova O
National University of Pharmacy, Kharkiv, Ukraine
objeCtives: A lifelong nature of COPD therapy requires significant costs from the 
patient’s budget. GOLD develops recommendations for the treatment of COPD, which 
correspond to the modern level of medicine and ensure proper quality of patients’ 
lives. The aim of this work is to identify the availability of drugs recommended by 
GOLD for patients in Ukraine from the perspective of physical availability of the 
drug in a pharmacy and in terms of its affordability. Methods: To determine the 
affordability of drugs, the paying capacity adequacy rate (Ca.s.) for 2014 was calcu-
lated. Results: In the Ukrainian market, there are 18 out of 32 drugs recommended 
by GOLD for the treatment of stable COPD course. A group of long-acting anticholin-
ergics (2 out of 4 drugs) and combined drugs glucocorticosteroids + β 2-agonists in 
one inhaler (2 out of 4 drugs) is presented insufficiently, and long-acting combina-
tions of anticholinergic + β 2-agonists are not available in the market. According to 
capacity adequacy rate (Ca.s.), in 2014 a month of treatment with the studied drugs 
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lization data. Results: The review allowed retrieving 4,768 studies and 11 fulfilled 
the eligibility criteria. Two articles presented their results in terms of correlation 
coefficient that were all statistically significant. The first one determined a correla-
tion between FEV1 and inhaled corticosteroids (ICS) use with an R-value of -0.42 and 
between sputum eosinophils and ICS use with an R-value of 0.3. The second article 
evaluated the correlation between PEF and hospitalization rates and concluded to 
a correlation with an R-value of -0.51. A total of 9 articles presented raw data that 
could be used to establish a correlation between lung function or eosinophil levels 
and resource utilization. Seven studies presented data that indicate an inverse cor-
relation between FEV1 and hospitalizations with decreased hospitalization rates, 
when FEV1 increases. Three studies indicate decreased emergency departments 
visit rates when FEV1 increases. Two studies also indicate an increased emergency 
department visit rates, when blood eosinophil levels increase. ConClusions: 
The correlation coefficients found in the systematic review indicate that when 
lung function improves or sputum eosinophil decreases, the resource utilization 
decreases. Furthermore, non-correlation studies that look at the same parameters 
support this hypothesis and suggest there may be a correlation between emergency 
department’s visits and blood eosinophil levels.
PRS79
the oPPoRtunitieS of inteRnet teChnology And telemediCine in 
inteRACtion between doCtoR And PAtient
Namazova-Baranova L, Vishneva E, Smirnov V, Antonova E, Alekseeva A, Levina J, 
Efendieva K, Dobrynina E, Tomilova A, Voznesenskaya N, Selimzianova L, Promyslova E
Scientific Centre of Children Health, Moscow, Russia
objeCtives: The characteristic properties of the modern healthcare system are 
presented by integration of information technology capabilities and harmonization 
of their use in industry. Aim. To create new system of telecommunication interaction 
between doctor and patient – specialized internet portal. Methods: The study was 
carried out to create web portal. The software project - shell management website 
with two interfaces: for professionals and patients was developed. Simultaneously 
with design and creation of an internet portal, 156 children with bronchial asthma 
(BA) were examined and their medical data were reviewed. Results: 19 children 
with severe atopic persistent uncontrolled BA (68% boys; mean age 13.6; basic 
therapy - 875 mcg fluticasone in combination with long-acting ß2-agonist and 
Omalizumab, the average dose - 450 mg / 4 weeks) were included in the project and 
had received the personal individual access (a couple of unique login/password to 
own page). The personal page after entering the own individual login / password 
allows patient to type in synchronous/asynchronous mode indicators of peak flow, 
symptoms, using of basic therapy and rescue medication in a special tables, the 
level of asthma control (ACT- test), and remotely – to ask a question to specialist. 
Patients with severe BA exacerbations, who were in the intensive care unit, also 
patients who don’t perceive long-term significant decline in respiratory function, 
had issued devices to determine oxygen saturation (SpO2, pulsoximeter) to moni-
tor this indicator and to exclude development of life-threatening conditions. The 
specialist interface contains information about each patient to evaluate remotely 
in synchronous/asynchronous mode patient condition, therapy adherence and con-
trol of BA ConClusions: The results of preliminary analysis of using of this web 
portal show increase of adherence to prescribed treatment, improving of quality of 
life, reduction the incidence of exacerbations, that confirms clinical and economic 
feasibility of using internet technologies.
PRS80
effeCtS of CliniCAl ComPuting SyStemS duRing ConSultAtionS on 
Smoking CeSSAtion - evidenCe lAndSCAPe fRom RAndomized And 
quASi RAndomized tRiAlS
Kohli IS
University of Dundee, Dundee, UK
objeCtives: Previous research to determine the effectiveness of web or computer 
based interventions, designed to reduce smoking have been reported. However, 
a lacuna regarding the use of same during consultations exists. The objective 
of this review was to improve understanding of the role of clinical computing 
systems during consultations on smoking cessation in general dental, medical, 
and community based practices or hospitals. Methods: The Cochrane Library, 
PubMed, ISI Web of Knowledge, EMBASE, and Google Scholar were accessed up to 
January 2010 using a combination of various Medical Subject Headings and other 
keywords to retrieve relevant studies not restricted to any geography. Studies 
were included based on a range of predefined inclusion criteria. Each study was 
quality scored (0-10) using a validated scoring system. The PRISMA checklist was 
used as the critical appraisal tool. Pre-developed forms were employed for extract-
ing the data. Results: Five studies fulfilled the selection criteria. A descriptive 
comparison was drawn between different studies since a meta-analysis was not 
possible as results for the I2 statistic were approximately 50%, indicating moder-
ate heterogeneity. A comparison of interventions was performed after extracting 
data from two studies using ExcelTM spread sheets, and presented as a forest 
plot. Findings indicated positive impact of clinical computing systems in physi-
cian consultations in increasing smoking abstinence in patients by 2% in clinical 
decision support system (CDSS) to up to 12 % (tailored letters). ConClusions: 
Tailored letters proved more effective when compared to brief advice and CDSS. 
Multi-faceted approaches involving elements of behavioral sciences, epide-
miology, health promotion and health informatics will be the key for future 
research.
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PhySiCiAnS’ PReSCRibing PAtteRn foR tubeRCuloSiS: evidenCeS fRom 
Community PhARmACieS in PunjAb, PAkiStAn
Iqbal MS1, Iqbal MZ2, Iqbal MW3, Bahari MB2
1Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan. Department of Clinical 
Pharmacy, Faculty of Pharmacy, MAHSA University, Selangor, Malaysia, 2Department of Clinical 
hospital admissions. Results: The study cohort included 36,914 patients (GOLD 
A: 33.8%, GOLD B: 21.0%, GOLD C: 18.1%, GOLD D: 27.0%). Average age at diagnosis 
was 66 years; 52.0% were male. Annual exacerbation rates increased with sever-
ity of COPD, ranging from GOLD A 0.83 (95% CI: 0.81–0.85) to GOLD D 2.51 (95% 
CI: 2.47–2.55) exacerbations per person-year (PPY). Annual rates of GP visits also 
increased with disease severity, from GOLD A 4.82 (95% CI: 4.74–4.93) to GOLD D 
7.44 (95% CI: 7.31–7.61) visits PPY. COPD-related hospitalisations increased with 
symptom severity from less (GOLD A: 0.28, GOLD C: 0.39 admissions PPY) to more 
symptoms (GOLD B: 0.52, GOLD D: 0.84 admissions PPY). No differences were 
observed across severity groups in non-COPD hospitalisations. ConClusions: 
Patients in the most severe category (GOLD D) experienced nearly three times the 
number of exacerbations and COPD-related hospital admissions as those in the 
least severe category (GOLD A). Management of COPD in earlier stages to stabilize 
disease progression could be beneficial for reducing exacerbation frequency and 
healthcare resource utilisation.
PRS76
ReliAbility of mAnufACtuReRS’ budget imPACt eStimAteS foR 
eliminAtion diet in PAtientS with AlleRgy to Cow’S milk in PolAnd
Tatara T1, Iwanczuk T1, Zawodnik S1, Sliwczynski A2, Brzozowska M2
1Agency for Health Technology Assessment and Tariff System in Poland (AOTMiT), Warsaw, 
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objeCtives: To compare the total value of payer’s expenditures on Nutramigen 
LGG 1, Nutramigen LGG 2, Neocate LCP, Neocate Advance in patients with allergy to 
cow’s milk protein estimated in the manufacturers’ Budget Impact Analyses (BIAs) 
submitted with the reimbursement applications to AOTMiT and actual expenditures 
of the National Health Fund (NHF). Methods: Annual public payer’s expenditures 
estimated in manufacturers’ BIAs for Nutramigen LGG 1/2, Neocate LCP/Advance 
and actual expenditures reported by the NHF were compared. RSSs were not taken 
into account. Analysed drugs were chosen on the basis of the same indication. 
Actual expenditures and number of package were taken from the financial reports of 
the NHF for the first and second year of the reimbursement for each drug. Results: 
For drugs Nutramigen LGG1/2 and Neocate LCP/Advance in patients with allergy 
to cow’s milk protein, the sum of total expenditures estimated in BIA submitted 
with the reimbursement applications was 55,158 million PLN in the first year and 
57,637 million PLN in the second year, and they were higher than the actual expen-
ditures reported by the NHF: 5,3 million PLN and 16,14 million PLN, respectively. 
The expenditures estimated in BIAs were overestimated by 939% in the first year 
of the reimbursement and 257% in the second year of reimbursement. The number 
of packages of the Nutramigen LGG 1/2, Neocate LCP/Advance also were analysed. 
The number of reimbursed packages estimated in BIAs in comparison to its actual 
number from the NHF reports was overestimated by 2029% in the first year and 
492% in the second year of reimbursement. ConClusions: In the case of drugs 
chosen for this analysis, total payer’s expenditures estimated in BIAs submitted with 
the reimbursement applications were overestimated in comparison to the real life 
expenditures of the NHF in Poland.
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ReSouRCe uSe And heAlth CARe CoStS of CoPd PAtientS At the end of 
life: A SyStemAtiC Review
Faes K1, De Frène V1, Cohen J2, Annemans L1
1University of Ghent, Ghent, Belgium, 2Vrije Universiteit Brussel, Brussels, Belgium
objeCtives: Patients with COPD in their final months of life place a potentially 
high burden upon healthcare systems. The aim of this systematic review was to 
describe the resources used and costs incurred by patients with COPD at the end-
of-life. Methods: We performed a comprehensive literature search in Medline, 
Web of Science and Econlit and evaluated and synthesized existing evidence on 
resource use and costs at the end-of-life in COPD patients. We screened 886 abstracts 
and reviewed 80 full-text manuscripts. Inclusion criteria were at least one type of 
resource use and/or cost outcome reported in adults diagnosed with COPD during an 
end-of-life period (varying between 3 years and 2 weeks before death). Subsequently, 
we performed quality appraisal consistent with the ISPOR checklist for retrospec-
tive database studies and accomplished comprehensive data extraction. Results: 
Nine studies fulfilled the inclusion criteria. Two, five and two studies described a 
European, North American and Asian healthcare setting, respectively. All studies 
had a retrospective design and were published between 2006 and 2014. We observed 
a very variable use of healthcare resources. An increased number of hospitaliza-
tions, ICU stay, primary care consultations and medication prescriptions and a lack 
of utilization of formal palliative care services were found to be the key drivers 
of resource use and costs of COPD patients during end-of-life. Palliative care also 
had a positive impact on costs in those patients. ConClusions: Despite a small 
number of existing studies, we found that the extensive and variable resource use 
and related costs of COPD patients during end-of-life applies to different aspects 
of the healthcare system. Especially the use of palliative care services is presumed 
to be effective in cost reduction at the end-of-life.
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eoSinoPhil levelS And heAlth CARe ReSouRCe utilizAtion in ASthmA
Lachaine J1, Bibeau J1, Castonguay A1, Piché-Richard V1, Barakat S2
1University of Montreal, Montreal, QC, Canada, 2Teva Canada Innovation, Montreal, QC, Canada
objeCtives: Asthma is a very common chronic disease that can cause a significant 
economic burden. The objective of this review was to explore the evidence on the 
possible correlation between lung function or eosinophil levels and resource utiliza-
tion in asthmatic patients. Methods: A literature search was made using keywords 
such as “asthma”, “eosinophil”, “respiratory function”, “resources”, and “costs”. The 
search was conducted in the electronic databases MEDLINE, EMBASE and PubMed 
from January 2000 to February 10th, 2015. To be eligible, studies had to focus on asth-
matic patients, include pulmonary or eosinophil measurements, and resource uti-
